Respiratory Syncytial Virus (RSV) Therapeutics Market
Global Respiratory Syncytial Virus (RSV) Therapeutics Market- Snapshot
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. A RSV infection can lead to serious problems such as bronchiolitis and pneumonia. In terms of revenue, the global respiratory syncytial virus (RSV) therapeutics market was valued at US$ 841.4 Mn in 2016 and is anticipated to reach more than US$ 2100.0 Mn by 2025, expanding at a CAGR of 11.7% from 2017 to 2025. Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are likely to fuel the global respiratory syncytial virus (RSV) therapeutics market from 2017 to 2025.
RSV is a common cause of bronchiolitis and pneumonia in babies. RSV is spread from respiratory secretions through close contact with infected persons. RSV does not usually occur until a baby is 4 to 6 week old. No specific approved drug or vaccine has been available to treat or prevent RSV infection till date. Patients are treated only by administering prophylaxis drugs. Key players are focusing on the development of new drugs and vaccines with better efficacy. NOVAVAX, Inc. is projected to launch the RSV F vaccine to prevent RSV infection in 2020, which in turn is likely to fuel the global respiratory syncytial virus (RSV) therapeutics market in the near future. However, the high price of prophylaxis drugs and a lack of return of investment in antiviral drugs are likely to hamper the global respiratory syncytial virus (RSV) therapeutics market during the forecast period.
There are several unmet needs in global respiratory syncytial virus (RSV) therapeutics market, which create significant opportunities for existing players and new entrants in the global market. Biologics provide ample opportunities for players operating in the global respiratory syncytial virus (RSV) therapeutics market. Recent ongoing developments in biologic anti respiratory syncytial virus (RSV) drugs such as GlaxoSmithKline’s GSK 3003891A, ReViral Ltd RV521, Bavarian Nordic’s MVA-BN-RSV uncovers the potential of these drugs.
The global respiratory syncytial virus (RSV) therapeutics market can be segmented based on drug type, dosage form, distribution channel, and geography. In terms of drug type, the palivizumab segment led the market and is expected to continue its dominance during the forecast period, followed by the ribavirin drug segment. Increasing utilization of palivizumab and development of new bio similar drug of palivizumab such as CT-P14 is likely to propel the segment during the forecast period. In terms of dosage form, the injectable form segment led the market, in terms of revenue, in 2016. The segment is projected to maintain its dominant position in the market during the forecast period. The others segment, which includes (inhalation etc.), is likely to lose market share during the forecast period owing to the preference for injectable to deliver drugs. In terms of distribution channel, drug stores and retail pharmacies was the leading segment of the market in 2016. It is likely to hold a leading share of the market during the forecast period.
In terms of geography, North America held a major share of the global respiratory syncytial virus (RSV) therapeutics market in 2016. Increasing prevalence of RSV infection among infants and the rise in awareness about the effect of the infection are likely to drive the market in North America. The market in Europe and Asia Pacific is projected to gain market share during the forecast period and is likely to account for a significant share of the market, in terms of revenue, in the near future. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and financial support for research and development for antiviral drugs in countries such as Brazil, South Africa, etc. are likely to boost the market in Latin America and Middle East and Africa.
Key companies operating in the global respiratory syncytial virus (RSV) therapeutics market and profiled in the report include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share. For instance, in June 2014, Ark Bioscience, (a China-based startup biotechnology company) signed an agreement with F. Hoffmann-La Roche Ltd. and under this agreement, the Roche’s drug candidate AK0529 (to treat RSV infection) is expected to further developed and marketed by Ark Bioscience, for which Roche is anticipated to get royalty payment.
The global respiratory syncytial virus (RSV) therapeutics market has been segmented as follows:
|
Drugs Type |
|
|
Dosage Form |
|
|
Distribution Channel |
|
|
Geography |
|
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary : Global Respiratory Syncytial Virus (RSV) Therapeutics Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis – Respiratory Syncytial Virus (RSV) Therapeutics Market
4.4. Epidemiology Assessment - Respiratory Syncytial Virus (RSV) Therapeutics Market
4.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, 2015-2025
4.5.1. Market Revenue Projection (US$ Mn)
4.5.2. Market Outlook
4.6. Key Trends
Chapter 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Drugs Type
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drugs Type, 2016–2025
5.3.1. Palivizumab
5.3.2. Ribavirin
5.3.3. Others
5.4. Market Attractiveness, by Drugs Type
Chapter 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Selection Technique
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast, by Dosage Form, 2016–2025
6.3.1. Oral
6.3.2. Injectable
6.3.3. Others
6.4. Market Attractiveness, by Dosage Form
Chapter 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast, by Distribution Channel, 2017–2025
7.3.1. Drug Stores & Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel
Chapter 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value and Volume Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
Chapter 9. North America Respiratory Syncytial Virus (RSV) Therapeutics Analysis and Forecast
9.1. Market Value Forecast, by Country , 2016–2025
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Forecast, by Drugs Type, 2016–2025
9.3. Market Value Forecast, by Dosage Form, 2016–2025
9.4. Market Value Forecast, by Distribution Channel, 2016-2025
9.5. Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Drugs Type
9.5.3. By Dosage Form
9.5.4. By Distribution Channel
9.6. Key Trends
Chapter 10. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Forecast, by Drugs Type, 2016–2025
10.3. Market Value Forecast, by Dosage Form, 2016–2025
10.4. Market Value Forecast, by Distribution Channel, 2016-2025
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Drugs Type
10.5.3. By Dosage Form
10.5.4. By Distribution Channel
10.6. Key Trends
Chapter 11. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Forecast, by Drugs Type, 2016–2025
11.3. Market Value Forecast, by Dosage Form, 2016–2025
11.4. Market Value Forecast, by Distribution Channel, 2016-2025
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Drugs Type
11.5.3. By Dosage Form
11.5.4. By Distribution Channel
11.6. Key Trends
Chapter 12. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Forecast, by Drugs Type, 2016–2025
12.3. Market Value Forecast, by Dosage Form, 2016–2025
12.4. Market Value Forecast, by Distribution Channel, 2016-2025
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Drugs Type
12.5.3. By Dosage Form
12.5.4. By Distribution Channel
12.6. Key Trends
Chapter 13. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Forecast, by Drugs Type, 2016–2025
13.3. Market Value Forecast, by Dosage Form, 2016–2025
13.4. Market Value Forecast, by Distribution Channel, 2016-2025
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Drugs Type
13.5.3. By Dosage Form
13.5.4. By Distribution Channel
13.6. Key Trends
Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Merck & Co., Inc.
14.1.2. F. Hoffmann-La Roche Ltd.
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. AstraZeneca plc. (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Merck 7 Co., Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. AbbVie, Inc. (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Valeant Pharmaceuticals International, Inc. (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. GlaxoSmithKline plc. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. ReViral Ltd. (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Gilead Sciences, Inc. (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. MEDIVIR AB (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Teva Pharmaceuticals Industries Ltd. (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
List of Tables
Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type/Vaccine, 2015–2025
Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form 2015–2025
Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 2015–2025
Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/ Sub-Region, 2015–2025
Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub Region, 2015–2025
Table 22: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 23: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 24: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025a
List of Figures
Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 02: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Type of Drugs/Vaccine (2016)
Figure 03: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Dosage Form (2016)
Figure 04: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Distribution Channel (2016)
Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drug Type/Vaccine, 2016 and 2025
Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Palivizumab, 2015–2025
Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Ribavirin, 2015–2025
Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Others, 2015–2025
Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type/Vaccine, 2017–2025
Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form, 2016 and 2025
Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Oral, 2015–2025
Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Injectable, 2015–2025
Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Others, 2015–2025
Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Dosage Form, 2017–2025
Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel, 2016 and 2025
Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Drug Stores and Retail Pharmacies, 2015–2025
Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies 2015–2025
Figure 18: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Others, 2015–2025
Figure 19: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Distribution Channel, 2017–2025
Figure 20: Global Respiratory syncytial virus (RSV) Therapeutics Market Value Share, by Region, 2016 and 2025
Figure 21: Respiratory Syncytial virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2016–2024
Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2017 and 2025
Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 27: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 28: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 29: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 30: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub-Region, 2016 and 2025
Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 36: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 37: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 38: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 39: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 45: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 46: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 47: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 48: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 54: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 55: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 56: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 57: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub Region, 2016 and 2025
Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub Region, 2017–2025
Figure 61: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 62: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drugs Type, 2017–2025
Figure 63: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 64: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 65: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 66: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 68: R&D Intensity (US$ Bn), 2015–2016
Figure 69: Breakdown of Net Sales of Diabetes Care Business Area, by Region 2016
Figure 70: Breakdown of Net Sales, by Diagnostic Division, 2016
Figure 71: Breakdown of Net Sales, by Region, 2017 (%)
Figure 72: R&D Intensity and Sales & Marketing Intensity – Company Level, (US$ Bn), 2016–2017
Figure 73: Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 74: Breakdown of Net Sales, (by Business Segment), 2017
Figure 75: Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 76: R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 77: Breakdown of Net Sales, by Region (Company Level), 2016
Figure 78: Breakdown of Net Sales, (Overall Company Level), 2016
Figure 79: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 80: Breakdown of Net Sales, by Region, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes